Year
Edition number
№5 / 2026
ORIGINAL STUDIES
A.G. Kononova, S.V. Kolbasnikov, E.V. Mashkina, G.D. Bolkhovitin
Peculiarities of clinical manifestations and comorbidities in adult patients with Gilbert’s syndrome9-14
O.V. Knyazev, M.A. Priymak, A.V. Kagramanova, A.A. Lishchinskaya, N.A. Fadeeva, A.N. Demchenko
Evaluation of the efficacy and safety of the combined use of 5-aminosalicylic acid and genetically engineered biological drugs in patients with moderate ulcerative colitis15-27
G.S. Dzhulay, A.D. Ivanova, T.E. Dzhulay, I.A. Zyabreva
Saint’s Triad and the dysplasia-dependent phenotype of patients in the context of multimorbidity28-34
L.Yu. Ilchenko, B.M. Taraki, H. Azizulla, I.G. Adamova, L.A.Kh. Babarzai, I.G. Fedorov, I.G. Nikitin
Hyperammonemia in patients with acute decompensation of hepatic cirrhosis35-44
M.V. Zlobin, D.I. Abdulganieva, N.A. Dubova
Efficacy of a modern treat-to-target strategy in patients with Crohn’s disease: Results of a 52-week clinical observation45-54
A.O. Kutsayeva, M.A. Nikonorova, M.A. Sinkov, E.Yu. Plotnikova
Chronic gastritis: Clinical, diagnostic, psychovegetative peculiarities and life quality of the patients56-65
B.B. Dambaeva, E.V. Onuchina, I.V. Temnikova
Clinical and functional correlations between gastroesophageal reflux disease and obstructive sleep apnea syndrome66-79
E.Yu. Plotnikova, L.G. Vologzhanina, S.R. Druzhinina, M.A. Sinkov, Yu.V. Kotelevtsev
Pleiotropic effects of hymecromone in the treatment of chronic liver and biliary tract diseases80-91
Yu.V. Cheremukhina, N.Yu. Borovkova
Cardiometabolic index as a new predictor of non-alcoholic fatty liver disease: Potential for use it in diagnosis and evaluation therapy92-96
V.I. Mazurov, E.S. Melnikov, E.A. Trofimov, O.V. Inamova, R.R. Samigullina, A.L. Chudinov, D.B. Aliev, K.P. Morozova
Clinical and laboratory efficacy of levilimab therapy in patients with rheumatoid arthritis in real-world clinical practice97-107
REVIEWS
D.A. Gavrilenko, O.V. Gaus, M.A. Livzan
Irritable bowel syndrome and functional dyspepsia: Mechanisms of comorbidity108-118
A.M. Osadchuk, I.D. Loranskaya, E.V. Stepanova
Postcholecystectomy syndrome: Diagnosis and treatment problems119-129
L.A. Lyubskaya, N. Thanh Lam
Parkinson’s disease: New methods of stimulation of deep brain structures and the role of the intestinal microbiome in pathogenesis (literature review)130-139
GUIDELINES FOR PRACTITIONERS
E.M. Mironova, G.L. Yurenev, D.S. Bordin
Advantages of 24-hour pH-impedance measurement in diagnosis and optimization of treatment approaches to gastroesophageal reflux disease in obese patients: Clinical observations140-146
N.V. Pyrikova, I.V. Osipova, D.V. Petrova, S.I. Kytmanova
A clinical case of oligosymptomatic «amiodaron lung» clinical course147-153
LECTURE
L.V. Tarasova, Yu.V. Tsyganova, A.A. Nikolaev
Diagnosis of extraintestinal manifestations of inflammatory bowel disease: A review154-163
Guideline for practitioners
G.G. Ketova, O.M. Shamina, A.I. Dolgushina
From the “gold standard” to a personalized approach: The place of triple therapy in case of H. pylori-associated diseases nowadays164-175
ACTUAL ISSUES OF PHARMACOTHERAPY AND PREVENTIVE TREATMENT
O.M. Drapkina, S.A. Berns
Peculiarities of proton pump inhibitors prescribing in patients with comorbid cardiovascular pathology and gastroesophageal reflux disease: Pharmacokinetic grounds for choice176-184
D.N. Andreev, I.V. Maev, D.S. Bordin, Yu.A. Kucheryavyy
Rebamipide in optimization of Helicobacter pylori eradication therapy: A review of evidence base186-195
Activities of RNMOT
Digest of interregional scientific and practical events under the aegis or with the participation of RSMSIM (May – June 2026)
196-208
